Clinical Outcomes of Oral Factor Xa-Inhibitor Associated Gastrointestinal Bleeds Treated with or without 4F-PCC among US Medicare Patients

被引：0
|
作者：
Williams, J.
Coleman, C., I
McNeil-Posey, K.
Dettling, T.
Li, S.
Guo, H.
Hoover, M.
机构：
[1] Texas Tech Univ, Sch Med, HSC, Amarillo, TX USA
[2] Univ Connecticut, Storrs, CT USA
[3] Portola Pharmaceut, San Francisco, CA USA
[4] Chron Dis Res Grp, Minneapolis, MN USA
来源：
ANNALS OF EMERGENCY MEDICINE | 2020年 / 76卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
67
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 18 条
  • [1] IMPACT OF TIMING OF 4F-PCC ADMINISTRATION ON OUTCOMES IN ORAL FACTOR XA INHIBITOR-ASSOCIATED ICH
    Jaszcz, Sarah
    Wein, Rachel
    Mangan, Kyle
    Mohamed, Wazim
    Parker, Dennis
    CRITICAL CARE MEDICINE, 2025, 53 (01)
  • [2] EVALUATION OF 4F-PCC IN THE MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH ORAL FACTOR XA INHIBITORS
    Deloney, Lindsay
    Tatum, Cassandra
    Weant, Kyle
    Eriksson, Evert
    Smith, Melanie
    CRITICAL CARE MEDICINE, 2019, 47
  • [3] TIME TO 4F-PCC AND BLOOD PRESSURE CONTROL IN FACTOR XA INHIBITOR-ASSOCIATED INTRACEREBRAL HEMORRHAGE
    Vilar, Jason
    Priano, James
    Rzasa, Kaitlin
    CRITICAL CARE MEDICINE, 2020, 48
  • [4] EVALUATION OF 4F-PCC IN OBESE VERSUS NON-OBESE PATIENTS FOR FACTOR XA INHIBITOR REVERSAL
    Ciborowski, Megan
    Nakajima, Steven
    Sparks, Eric
    McKinney, James, III
    CRITICAL CARE MEDICINE, 2020, 48
  • [5] EVALUATION OF FIXED-DOSE VERSUS WEIGHT-BASED DOSING OF 4F-PCC FOR ORAL FACTOR XA INHIBITOR BLEEDING
    Ellenburg, Jessica
    Beck, Julie
    Casey, Jessica
    Kallenberger, Michael
    John, Jeremy
    Musselman, Megan
    CRITICAL CARE MEDICINE, 2024, 52
  • [6] Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
    Melanie N. Smith
    Lindsay Deloney
    Cassandra Carter
    Kyle A. Weant
    Evert A. Eriksson
    Journal of Thrombosis and Thrombolysis, 2019, 48 : 250 - 255
  • [7] Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
    Smith, Melanie N.
    Deloney, Lindsay
    Carter, Cassandra
    Weant, Kyle A.
    Eriksson, Evert A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (02) : 250 - 255
  • [8] Clinical outcomes following administration of 4F-PCC for management of bleeding or need for emergent procedure on a Xa inhibitor - good enough, or do we need other agents?
    Wychowski, Maura K.
    Ruscio, Christina I.
    Sham, Ronald L.
    Kouides, Peter A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 608 - 608
  • [9] Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
    S. Scott Sutton
    Joseph Magagnoli
    Tammy H. Cummings
    Theresa Dettling
    Belinda Lovelace
    Mary J. Christoph
    James W. Hardin
    Journal of Thrombosis and Thrombolysis, 2023, 56 : 137 - 146
  • [10] Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
    Richard J Buka
    David J Sutton
    Phillip LR Nicolson
    Journal of Thrombosis and Thrombolysis, 2024, 57 : 739 - 741
12